03

Sep

2006

Class Il Radiometer America Inc

0

Company:Radiometer America Inc.
Date of Enforcement Report:8/16/2006
Class:lI

PRODUCT
a) Blood Gas and Co-Ox Electrolyte & Metabolyte Analyzer,
ABL-700 series, Recall # Z-1317-06;
b) Blood Gas and Co-Ox Electrolyte & Metabolyte Analyzer,
ABL-800 series, Recall # Z-1318-06

REASON
Software defect. pO2 and pCO2 sample test results run on the firm’s ABL700/800 Series Blood Gas Analyzers are not being properly flagged during the sample calibration phase..

CODE
a) All analyzers manufactured from 1/1999-12/2005. The devices
contain serial numbers 902-441RxxxNxxx. The Rxxx number
denotes manufacturing run, and the Nxxx number denotes the
individual instrument within the run;
b) All analyzers manufactured from 1/2005-10/31/2005. The devices
contain serial numbers 902-441RxxxNxxx. The Rxxx number
denotes manufacturing run, and the Nxxx number denotes the
individual instrument within the run.

RECALLING FIRM/MANUFACTURER
Recalling Firm: Radiometer America Inc, WestlakeOH, by letter on June 17, 2005
Manufacturer: Radiometer Medical ApS, Bronshoj, Denmark. Firm initiated recall is complete.

VOLUME OF PRODUCT IN COMMERCE
Series 700 — 1,635 Analyzers;
Series 800 — 108 Analyzers

DISTRIBUTION
Nationwide

About the author

Amy Sellers

Amy enjoys researching and writing about developments in medical technology and how that intersects with US law. She received her J.D. from the University of Florida Levin College of Law in 2020 and now works as a Regulatory Associate for SoftwareCPR®, a general-purpose regulatory consulting firm that is recognized globally for their expertise with standards and national regulations pertaining to medical device, mobile medical app, and HealthIT software.

Being Agile & Yet Compliant (Public)

Our SoftwareCPR unique approach to incorporating agile and lean engineering to your medical device software process training course is now open for registration!

Agile principles that align well with medical
Backlog management
Agile risk management
Incremental and iterative software development lifecycle management
Frequent release management
And more!

3 days virtual (Zoom) with group exercises, quizzes, examples, Q&A.

Lead Instructor: Mike Russell

Next public offerings:

Americas: 11-13 February 2025
EU/Eastern Europe/Middle East/Africa/Atlantic/eastern South America: 18-20 February 2025
Southern Central Northeastern Pacific: 24-26 February 2025

See our post titled: 1st Quarter 2025 Agile Compliant Courses Scheduled

IEC 62304 and other emerging standards for Medical Device and HealthIT Software

Our flagship course for preparing regulatory, quality, engineering, operations, and others for the activities and documentation expected for IEC 62304 conformance and for FDA expectations. The goal is to educate on the intent and purpose so that the participants are able to make informed decisions in the future. Focus is not simply what the standard says, but what is meant and discuss examples and approaches one might implement to comply. Special deep discount pricing available to FDA attendees and other regulators.

3-days onsite with group exercises, quizzes, examples, Q&A.

Instructor: Brian Pate

Next public offering: June 24-26, 2025 (Boston, MA)

Special pre-registration discount through January 31, 2025

Private, in-house courses can be scheduled. Contact us.

Email training@softwarecpr.com for more info.

Medical Device Cybersecurity (Public or Private)

This course takes a deep dive into the US FDA expectations for cybersecurity activities in the product development process with central focus on the cybersecurity risk analysis process. Overall approach will be tied to relevant standards and FDA guidance documentation. The course will follow the ISO 14971:2019 framework for overall structure but utilize IEC 62304, IEC 81001-5-1, and AAMI TIR57 for specific details regarding cybersecurity planning, risk characterization, threat modeling, and control strategies.

2-days onsite with group exercises, quizzes, examples, Q&A.

Instructor: Dr Peter Rech, 2nd instructor (optional)

Next public offering: TBD